ESTRO 2024 - Abstract Book

S1841

Clinical - Mixed sites, palliation

ESTRO 2024

[2] Smith, A.B., Cocks, K., Parry, D. and Taylor, M., 2014, October. The Functional assessment of Cancer Therapy Prostate (FACT-P) & Trial Outcomes Index (TOI): a Rasch analysis. In QUALITY OF LIFE RESEARCH (Vol. 23, pp. 99-99). VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS: SPRINGER. [3] King, M.T., Cella, D., Osoba, D., Stockler, M., Eton, D., Thompson, J. and Eisenstein, A., 2010. Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Related Outcome Measures, pp.119-126.

326

Proffered Paper

ESMO-ESTRO consensus recommendations on the safety of combining targeted therapies with radiotherapy

Evert S.M. van Aken 1 , Dirk De Ruysscher 2,3 , Jorge Barriuso 4,5 , Luis Castelo-Branco 6 , Bharti Devnani 7 , Ajeet K. Gandhi 8 , Sean M. O'Cathail 9 , Arsela Prelaj 10,11 , Claus Belka 12 , Florian Lordick 13 , Corrie A.M. Marijnen 1,14 , Umberto Ricardi 15 , Monique C. de Jong 1 , George Pentheroudakis 6 1 Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Radiation Oncology, Amsterdam, Netherlands. 2 Maastricht University Medical Center+, Department of Radiation Oncology (Maastro), Maastricht, Netherlands. 3 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, Netherlands. 4 School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 5 The Christie NHS Foundation Trust, Department of Medical Oncology, Manchester, United Kingdom. 6 ESMO - European Society for Medical Oncology, Scientific and Medical Division, Lugano, Switzerland. 7 All India Institute of Medical Sciences, Department of Radiation Oncology, Jodhpur, India. 8 Dr. Ram Manohar Lohia Institute of Medical Sciences, Department of Radiation Oncology, Lucknow, India. 9 University of Glasgow, School of Cancer Sciences, Glasgow, United Kingdom. 10 Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology, Milan, Italy. 11 Politecnico di Milano, Department of Electronics, Information Technology, and Bioengineering, Milan, Italy. 12 University Hospital, LMU Munich, Department of Radiation Oncology, Munich, Germany. 13 University Cancer Center Leipzig, University of Leipzig Medical Center, Department of Medicine, Leipzig, Germany. 14 Leiden University Medical Center, Department of Radiation Oncology, Leiden, Netherlands. 15 University of Turin, Department of Oncology, Turin, Italy

Purpose/Objective:

The introduction of targeted therapies and immunotherapy has improved survival outcomes for many cancer types. Patients receiving these therapies are frequently referred for radiotherapy (RT). Although combined therapy with RT may improve treatment outcomes, these combinations may also lead to increased toxicity. High-quality toxicity data on combined therapy are scarce and there is no international guideline or consensus on whether or how to combine these systemic therapies with RT. The goal of this joint initiative was to systematically summarize all available toxicity data and to provide Delphi consensus recommendations regarding the safety of combined therapy.